Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double‐blind, parallel‐controlled, phase 1 study

Abstract The primary objective of this randomized, double‐blind, parallel‐controlled study (from December 2016 to October 2018) was to evaluate pharmacokinetic (PK) equivalence of adalimumab biosimilar HLX03 and reference adalimumab in healthy volunteers, and to assess safety, and immunogenicity of...

Descripció completa

Dades bibliogràfiques

Autors principals:	Hong Zhang, Min Wu, Jixuan Sun, Xiaoxue Zhu, Cuiyun Li, Yanhua Ding, Xiaodi Zhang, Katherine Chai, Xiaojiao Li
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2021-04-01
Col·lecció:	Pharmacology Research & Perspectives
Matèries:	adalimumab bioequivalence biosimilar pharmacokinetics
Accés en línia:	https://doi.org/10.1002/prp2.733
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!